Hepatorenal Syndrome

Clinical Case — HRS-AKI after SBP

A 58-year-old man with decompensated cirrhosis from alcohol-associated liver disease (MELD-Na 24, Child-Pugh C) was admitted 6 days ago with spontaneous bacterial peritonitis. He received cefotaxime and albumin per protocol (1.5 g/kg day 1, 1 g/kg day 3). SBP resolved on repeat paracentesis (PMN count <250/mm³). However, creatinine has risen progressively from 1.0 → 1.6 → 2.2 → 2.8 mg/dL over 5 days. Diuretics held since day 2. Urine output 400 mL/24 hours. Blood pressure 88/54 mmHg, MAP 65 mmHg.

Creatinine: 1.0 → 2.8 mg/dL over 5 days · Urine Na <20 mEq/L · UA: no casts, trace protein (<200 mg/day), no hematuria · Renal US: small echogenic kidneys, no hydronephrosis · MAP 65 mmHg

Work through the management step by step before the answers are revealed.

Type	Previous Name	Key Feature	Prognosis
HRS-AKI	Type 1 HRS	Serum creatinine rise ≥0.3 mg/dL within 48 hours OR ≥50% rise within 7 days, meeting full HRS diagnostic criteria	Median survival weeks without treatment; rapidly progressive; highest urgency for vasoconstrictor therapy and transplant listing
HRS-CKD	Type 2 HRS	Slower, more stable GFR reduction (<60 mL/min/1.73 m²) for >3 months meeting HRS criteria, without rapid acute deterioration	Often associated with refractory ascites; months-level prognosis; more amenable to outpatient vasoconstrictor trials

Pharmacologic treatment of HRS is vasoconstrictors + albumin. Vasoconstrictors reverse splanchnic vasodilation and reduce RAAS/SNS activation, restoring renal perfusion. Albumin serves as both a volume expander and an anti-inflammatory mediator (scavenges DAMPs and endotoxin).

First-Line (US, FDA-Approved)

Terlipressin + Albumin

Vasopressin V1 receptor agonist → splanchnic vasoconstriction → reverses RAAS activation
FDA approved September 2022 based on the CONFIRM trial (Wong F et al., NEJM 2021)
Dose: 1 mg IV q4–6h; titrate to 2 mg q4–6h if creatinine does not decline ≥25% by day 3
Monitor: peripheral ischemia, mesenteric ischemia, MI — pulse ox, skin perfusion, ECG
Contraindications: ischemic heart disease, severe PVD, respiratory failure (hold if SpO₂ <90%)

ICU Alternative

Norepinephrine + Albumin

Alpha-1 adrenergic agonist; efficacy comparable to terlipressin in RCTs and meta-analyses
Requires ICU admission and arterial line for continuous MAP monitoring
Dose: 0.5–3 mg/hour IV, titrated to MAP goal ≥10 mmHg above baseline
Preferred at centers without terlipressin and in patients requiring ICU regardless

Outpatient / Step-Down

Midodrine + Octreotide + Albumin

Less effective than terlipressin or norepinephrine; used when vasopressors unavailable
Midodrine: 7.5–12.5 mg PO TID (alpha-1 agonist, raises MAP)
Octreotide: 100–200 µg SQ TID (somatostatin analog; inhibits splanchnic vasodilators)
Most relevant for HRS-CKD or as bridge to transplant in outpatient setting

Albumin Dosing

Albumin is always co-administered with vasoconstrictors. Loading dose at initiation (1 g/kg on day 1, up to 100 g); then 20–40 g/day ongoing to maintain effective arterial volume expansion. Albumin acts not only as a volume expander but also scavenges oxidized lipids and endotoxin — contributing to benefit beyond simple fluid resuscitation.

Quick recall

1/2

What response threshold is used to define terlipressin efficacy at 48–72 hours?

Tap to reveal →

Liver Transplantation — Definitive Treatment

Liver transplantation is the only definitive treatment for HRS. Vasoconstrictor therapy serves as a bridge to transplantation, not a cure. Key principles: (1) Renal recovery after LT depends on duration and severity of HRS — patients who respond to terlipressin have significantly better post-LT renal outcomes. (2) Prolonged HRS-AKI (>4–8 weeks) increases risk of irreversible tubular injury → may require simultaneous liver-kidney (SLK) transplantation. (3) TIPS may be used in HRS-CKD to reduce portal pressure; limited evidence in HRS-AKI; contraindicated in advanced HE (grade ≥3) or severe hepatic dysfunction.

If none of the three OPTN criteria are met, proceed with liver transplant alone (safety-net kidney listing remains available).

Prevention Strategies

SBP Prophylaxis — Highest Evidence

Albumin in SBP

Sort et al. NEJM 1999 (Ginès P co-author): albumin at SBP treatment prevents HRS-AKI and reduces 3-month mortality
Dose: 1.5 g/kg albumin on day 1; 1 g/kg albumin on day 3
NNT ≈ 7 to prevent one episode of renal impairment
Standard of care — do not omit in any patient receiving antibiotics for SBP

Drug Avoidance

Nephrotoxin Avoidance

NSAIDs — prostaglandin inhibition removes the final renal afferent vasodilatory buffer; a single NSAID dose can precipitate AKI/HRS
Aminoglycosides — avoid in cirrhosis; if unavoidable, single daily dosing with levels
Iodinated IV contrast — use LOCM; pre-hydrate; MRI with gadolinium preferred
ACE inhibitors / ARBs — use cautiously; can reduce renal perfusion pressure with low MAP

Diuretic Management

Avoid Overdiuresis

Target weight loss ≤0.5 kg/day (no peripheral edema) or ≤1 kg/day (peripheral edema present)
Hold diuretics and check BUN/creatinine if rising, urine output falling, or orthostasis
LVP >5 L: albumin 8 g per litre removed to prevent post-paracentesis circulatory dysfunction (PPCD); current AASLD 2021 (PMID 33942342) and EASL 2010 (PMID 20633946) recommended dose

Pentoxifylline — Negative Evidence

Pentoxifylline is not recommended for HRS prevention. While it was studied in severe alcoholic hepatitis (STOPAH trial, Thursz et al., NEJM 2015, PMID 25901427), it demonstrated no benefit for mortality at any timepoint. It is no longer recommended for HRS prevention in alcoholic hepatitis.

Quick recall

1/2

A colleague questions why you combine albumin with terlipressin in HRS-AKI rather than using the vasopressin analogue alone. What is the physiological rationale for combination therapy?

Tap to reveal →

Hepatorenal Syndrome

Prevention Strategies

References